Breast Cancer | Specialty

Charles Perou on Biomarker Assay Use in ASCO Breast Cancer Guideline

April 8th 2016

Charles M. Perou, PhD, May Goldman Shaw Distinguished Professor of Molecular Oncology, professor of Genetics, and Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, discusses the biomarker assay results as described in the ASCO breast cancer guideline.

Dr. William Gradishar on Updates in NCCN Breast Cancer Guidelines

April 4th 2016

William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.

NCCN Refines Recommendations for Breast Cancer Care

April 2nd 2016

At the 2016 NCCN Annual Conference, William J. Gradishar, MD, discussed updates to the NCCN Breast Cancer Guideline and the latest research developments in the field.

Dr. Salerno Discusses Hypofractionation for Early Breast Cancer

April 1st 2016

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses hypofractionated radiotherapy for the treatment of patients with early-stage breast cancer.

Neratinib Application Delayed for HER2+ Breast Cancer

March 30th 2016

Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.

Dr. Van Zee on Nomograms for Patients With DCIS

March 30th 2016

Kimberly J. Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses nomograms as a tool to determine the risk of recurrence for patients with ductal carcinoma in situ (DCIS).

ONT-380/T-DM1 Combo Shows Promise in HER2+ Breast Cancer With CNS Mets

March 28th 2016

Erika P. Hamilton, MD, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.

Dr. Boughey on Surgery in Patients With HER2+ Breast Cancer

March 28th 2016

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical approach for patients with HER2-positive breast cancer.

Physicians Put on the Gloves to Debate Best Treatments in Breast Cancer

March 26th 2016

Experts debated whether platinum-based or other additional systemic agents be used in high-risk triple-negative breast cancer, as well as other treatment discussions in breast cancer.

Expert Discusses Emerging Agents in ER+ Metastatic Breast Cancer

March 23rd 2016

Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.

Mittendorf Explains Growing Role of Checkpoint Inhibitors in Breast Cancer

March 21st 2016

Elizabeth Mittendorf, MD, PhD, discusses checkpoint inhibition studies in triple-negative breast cancer, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.

Preserving Flexibility in Chemo Decisions in Breast Cancer

March 18th 2016

The accumulation of evidence supporting a regimen of anthracycline and taxanes for breast cancer has led some oncologists to argue for the establishment of a standard treatment plan that deemphasizes or eliminates alternative options.

Dr. Seidman on Ixabepilone in Patients With Aggressive Breast Cancer

March 18th 2016

Andrew D. Seidman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the label indication for ixabepilone (Ixempra) for the treatment of patients with aggressive breast cancer.

Excessive Imaging in Early-Stage Breast Cancer Detailed in Study

March 17th 2016

A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.

3D Mammography Becoming Standard in Breast Cancer Screening, But Caution Advised

March 17th 2016

Constance D. Lehman, MD, PhD, explains how tomosynthesis, otherwise known as 3D mammography, is already recognized as the new standard of care in terms of breast cancer screening.

Studies Mark Progress Against Triple-Negative Breast Cancer

March 15th 2016

The antibody–drug conjugate sacituzumab govitecan (IMMU-132) received a breakthrough therapy designation based on phase II trial data showing a response rate of 31% in heavily pretreated patients with metastatic TNBC. However, treatment advances are lagging behind those seen in other breast cancer phenotypes.

Mittendorf Explains What's New With NeuVax in Breast Cancer

March 14th 2016

Elizabeth A. Mittendorf, MD, PhD, discusses nelipepimut-S (NeuVax), a peptide derived from HER2 protein combined with granulocyte-macrophage colonystimulating factor that is currently being investigated as a single-agent, in combination with standard-of-care therapies, and in multiple settings and subtypes of breast cancer.

Dr. von Minckwitz on Lessons Learned From Neoadjuvant Trials in Breast Cancer

March 13th 2016

Gunter von Minckwitz, MD, director of the German Breast Group Research Institute, discusses lessons learned from clinical trials examining neoadjuvant therapies in patients with breast cancer.

Dr. Borgen on Disconnect Between Practitioners on the USPSTF Breast Cancer Screening Guidelines

March 13th 2016

Differences Between the USPSTF and American Cancer Society Breast Cancer Screening Guidelines

March 13th 2016